Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 4/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527750 | 1.00 | CYP2C19 (0.79) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| SCHEMBL886903 | 0.98 | CYP2C19 (0.76) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| SCHEMBL886901 | 0.98 | CYP2C19 (0.76) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| SCHEMBL1133551 | 0.89 | CYP2C19 (1.00) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| SCHEMBL31707405 | 0.89 | CYP2C19 (1.00) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| Arsanilic Acid SCHEMBL160507 | 0.87 | KDM4E (1.00) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| Arsanilic Acid SCHEMBL4837583 | 0.87 | KDM4E (1.00) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| Arsanilic Acid SCHEMBL5051668 | 0.84 | KDM4E (0.95) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| Arsanilic Acid SCHEMBL31473003 | 0.84 | TSHR (0.95) | CYP2C19RAB9AKDM4ETSHRMAPT | |
| SCHEMBL886902 | 0.82 | CYP2C19 (0.53) | CYP2C19RAB9AKDM4ETSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2255175-A1 | MULTIPLEXED ANALYSIS METHODS USING SERS-ACTIVE NANOPARTICLES | Morpho Detection, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009102598-A1 | MULTIPLEXED ANALYSIS METHODS USING SERS-ACTIVE NANOPARTICLES | GENERAL ELECTRIC COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-1776125-A2 | FUNCTIONALIZED SINGLE WALLED CARBON NANOTUBES | HYPERION CATALYSIS INTERNATIONAL, INC. (US) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006130150-A2 | FUNCTIONALIZED SINGLE WALLED CARBON NANOTUBES | HYPERION CATALYSIS INTERNATIONAL, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-0910340-A4 | FUNCTIONALIZED NANOTUBES | HYPERION CATALYSIS INT (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040202603-A1 | graphitic nanotubes substituted with chemical moieties or upon which certain cyclic compounds are adsorbed; complex structures comprised of such functionalized fibrils linked to one another; introducing functional groups onto the surface of such fibrils | HYPERION CATALYSIS INTERNATIONAL, INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004066959-A2 | ORGANIC-ARSONIC COMPOUNDS | PARKER HUGHES INSTITUTE (US) | 2004-08-12 | — | — | WO | disclosed |
| US-6686344-B1 | TREATING CANCER, TUMORS | PAKER HUGHES INSTITUTE | 2004-02-03 | — | — | US | disclosed |
| EP-0910340-A1 | FUNCTIONALIZED NANOTUBES | HYPERION CATALYSIS INTERNATIONAL, INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997032571-A1 | FUNCTIONALIZED NANOTUBES | HYPERION CATALYSIS INTERNATIONAL, INC. (US) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202603-A1 | graphitic nanotubes substituted with chemical moieties or upon which certain cyclic compounds are adsorbed; complex structures comprised of such functionalized fibrils linked to one another; introducing functional groups onto the surface of such fibrils | FSCN1, CYCS, TUBA3C | CYP2C19 2370/4885RAB9A 3452/4885KDM4E 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.